Страна: Велика Британія
мова: англійська
Джерело: myHealthbox
butamirate citrate
Actavis Group PTC ehf
R05DB13
butamirate citrate
7.5mg/5ml
Syrup
Oral use
5 ml, 10 ml, 15 ml, 20 ml, 25 ml and 30 ml.
POM - Prescription Only Medicine
Balkanpharma Troyan AD
Other cough suppressants
Symptomatic treatment of non-productive cough.
Authorised
2015-04-30
2 PACKAGE LEAFLET: INFORMATION FOR THE PATIENT BUTAMIRATЕ 7.5MG/5ML SYRUP butamirate citrate READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. Always take this medicine exactly as described in this leaflet or as your doctor or pharmacist has told you. - Keep this leaflet. You may need to read it again. - Ask your pharmacist if you need more information or advice. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. - You must talk to a doctor if you do not feel better or if you feel worse after 4 to 5 days. - The full name of this medicine is Butamiratе 7.5mg/5ml Syrup but within the leaflet it will be referred to as Butamiratе Syrup. WHAT IS IN THIS LEAFLET 1. What Butamiratе Syrup is and what it is used for 2. What you need to know before you take Butamiratе Syrup 3. How to take Butamiratе Syrup 4. Possible side effects 5. How to store Butamiratе Syrup 6. Contents of the pack and other information 1. WHAT BUTAMIRATЕ SYRUP IS AND WHAT IT IS USED FOR Butamiratе Syrup contains the active ingredient butamirate citrate, which belongs to a group of medicines called antitussives. Butamiratе Syrup is used for the symptomatic treatment of non-productive (dry) cough. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE BUTAMIRATЕ SYRUP _ _ DO NOT TAKE BUTAMIRATЕ SYRUP if you are allergic to butamirate citrate or any of the other ingredients of this medicine (listed in section 6). Butamiratе Syrup must not be used in children or adolescents under 18 years of age. WARNINGS AND PRECAUTIONS Talk to your doctor or pharm Прочитайте повний документ
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Butamirate 7.5mg/5ml Syrup 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml of syrup contains 1.5 mg butamirate citrate equivalent to 0.924 mg butamirate. 5 ml of syrup contains 7.5 mg butamirate citrate equivalent to 4.62 mg butamirate. Excipient with known effect: 1 ml of oral suspension contains 450 mg of sorbitol. 1 ml of oral suspension contains 125 mg of glycerol. 5 ml of oral suspension contains 2250 mg of sorbitol. 5 ml of oral suspension contains 625 mg of glycerol. For the full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Syrup Colourless or pale yellow liquid. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Symptomatic treatment of non-productive cough. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology _ _ _Adults _ Recommended dose - 15 ml up to 4 times daily Treatment is limited to the symptomatic period. Medical advice should be sought if the cough lasts longer than 4-5 days or if fever, dyspnoea or chest pain develops. _Patients with renal or hepatic impairment_ Data is lacking in patients with impaired renal or hepatic function. Patients with renal and/or liver disease may be at greater risk for adverse effects from butamirate due to drug and metabolite accumulation. Method of administration Butamirate syrup should be taken orally. 4.3 CONTRAINDICATIONS - Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. - Children and adolescents under 18 years of age. 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE Before prescribing an antitussive treatment, the causes of the cough should be investigated to assess the need for aetiological treatment. If the cough persists after taking the antitussive treatment at the Прочитайте повний документ